Platelet-activating factor (PAF) is an important, perhaps pivotal, autacoid with a myriad of phlogistic actions which implicates this mediator in playing an important role in modulating many aspects of normal as well as abnormal (patho)physiological and inflammatory processes. Most all of our current understanding of the mechanisms underlying the (patho)biological actions of PAF has been derived from studies that employed only the hexadecyl-(C16:0) or octadecyl-(C18:0) alkyl chain PAF homologs. However, it is now well-documented that the PAF synthesized by stimulated neutrophils (PMN), as well as by other cells and tissues, is comprised of a heterogeneous family of sn-2 acetylated phospholipids. Moreover, there is now compelling evidence that various PAF homologs and analogs differ significantly from one another in their instrinsic in vitro and in vivo biological activities and potencies (e.g., platelet and PMN stimulation and cardiovascular and pulmonary alterations), possibly by interacting with different PAF receptor subtypes. Therefore, new research initiatives are required to rigorously elucidate the extent of PAF molecular heterogeneity and to characterize the (patho)physiological properties and mechanisms of action of the various PAF molecules. In this regard, the overall objective of the present study will be to address the following hypothesis: Modulation of the types and amounts of the various molecular species of PAF that are synthesized and released by the human PMN will significantly influence the extent and character of PAF-mediated tissue injury and dysfunction. Our investigations will focus on three Specific Aims: 1) Characterization of the molecular composition of the PAF that is synthesized and then either retained or released by human PMN after stimulation by different stimuli; 2) Elucidation of the influence of the intracellular and extracellular microenvironments on the molecular composition of the PAF that is synthesized and then either retained or released by stimulated human PMN; and 3) Characterization of the mechanistic basis for the autocrine actions (agonistic, synergistic, and/or antagonistic) of the PAF homologs and analogs that are synthesized by the human PMN. The results of these studies will provide new information which will be essential in our long-term efforts toward understanding the role of PAF in the modulation of acute inflammatory and allergic tissue injury and dysfunction.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL022555-14A1
Application #
3336934
Study Section
Pathology A Study Section (PTHA)
Project Start
1978-04-01
Project End
1995-11-30
Budget Start
1992-01-15
Budget End
1992-11-30
Support Year
14
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
McManus, L M; Bloodworth, R C; Prihoda, T J et al. (2001) Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia. J Leukoc Biol 70:395-404
McManus, L M; Pinckard, R N (2000) PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med 11:240-58
Weintraub, S T; Satsangi, R K; Sprague, E A et al. (2000) Mass spectrometric analysis of platelet-activating factor after isolation by solid-phase extraction and direct derivatization with pentafluorobenzoic anhydride. J Am Soc Mass Spectrom 11:176-81
Pinckard, R N; Prihoda, T J (1996) Alkyl-PAF and acyl-PAF human neutrophil priming for enhanced fMLP- and rC5a-induced superoxide anion production. J Leukoc Biol 59:219-28
Woodard, D S; Mealey, B L; Lear, C S et al. (1995) Molecular heterogeneity of PAF in normal human mixed saliva: quantitative mass spectral analysis after direct derivatization of PAF with pentafluorobenzoic anhydride. Biochim Biophys Acta 1259:137-47
Woodard, D S; Ostrom, K K; McManus, L M (1995) Lipid inhibitors of platelet-activating factor (PAF) in normal human plasma. J Lipid Mediat Cell Signal 12:11-28
Pinckard, R N; Woodard, D S; Showell, H J et al. (1994) Structural and (patho)physiological diversity of PAF. Clin Rev Allergy 12:329-59
Weintraub, S T; Lear, C; Pinckard, R N (1993) Differential electron capture mass spectral response of pentafluorobenzoyl derivatives of platelet activating factor alkyl chain homologs. Biol Mass Spectrom 22:559-64
McManus, L M; Woodard, D S; Deavers, S I et al. (1993) PAF molecular heterogeneity: pathobiological implications. Lab Invest 69:639-50
McManus, L M; Ostrom, K K; Lear, C et al. (1993) Radiation-induced increased platelet-activating factor activity in mixed saliva. Lab Invest 68:118-24

Showing the most recent 10 out of 36 publications